Abstract:Abstract Cyclin D1 is an important molecular driver of human breast cancer but better understanding of its oncogenic mechanisms is needed, especially to enhance efforts in targeted therapeutics. Activation of the cyclin D1 oncogene, often by amplification or rearrangement, is a major driver of multiple types of human tumors including breast and squamous cell cancers, B-cell lymphoma, myeloma, and parathyroid adenoma. The cyclin D1 gene is amplified or overexpressed in up to half of human breast cancers and its mammary-targeted overexpression induces mammary tumorigenesis in mice. Cyclin D1 encodes the regulatory subunit of the cyclin-dependent kinase (CDK) holoenzyme that phosphorylates several substrates including the retinoblastoma protein (pRb) to advance the G1S cell cycle checkpoint, promote DNA synthesis and regulate NRF-1 to inhibit mitochondrial biogenesis thereby coordinating nuclear and mitochondrial functions. In addition to cyclin D1's function as a regulatory subunit of a CDK holoenzyme, several CDK-independent functions have been identified. Tumors overexpressing cyclin D1 tend to display normal levels of proliferation and expression of E2F target genes, which contrasts with tumors overexpressing cyclin E or an activator for pRb. Breast cancers overexpressing cyclin D1 that are wild type for pRb have relatively normal proliferation rates, in contrast to those caused by genetic inactivation of pRb, which show significantly increased proliferation rates. Furthermore, the alternate splice form of cyclin D1, (cyclin D1b), has potent transforming ability, which does not correlate with the ability to phosphorylate the pRb protein. Several other properties of cyclin D1 have been identified including the induction of cellular migration and enhanced angiogenesis, inhibition of mitochondrial biogenesis, and mediating DNA-damage repair signaling. Cyclin D1 binding proteins participating in these putatively CDK-independent functions include PACSIN2, NRF1, and p27KIP1; binding to p27KIP1 and PACSIN2 contribute to the pro-migratory function of cyclin D1. Currently, pharmaceutical initiatives to inhibit cyclin D1 are focused on the catalytic component since the transforming capacity is thought to reside in the cyclin D1/CDK activity. We initiated the following study to directly test the oncogenic potential of catalytically inactive cyclin D1 in an in vivo mouse model that is relevant to breast cancer. Herein, transduction of cyclin D1-/- mouse embryonic fibroblasts (MEFs) with the kinase dead KE mutant of cyclin D1 led to aneuploidy, abnormalities in mitotic spindle formation, autosome amplification, and chromosomal instability (CIN) by gene expression profiling. Acute transgenic expression of either cyclin D1WT or cyclin D1KE in the mammary gland was sufficient to induce the CIN signature within 7 days. Sustained expression of cyclin D1KE induced mammary adenocarcinoma with similar kinetics to that of the wild-type cyclin D1. ChIP-Seq studies demonstrated recruitment of cyclin D1WT and cyclin D1KE to the genes governing CIN. We conclude that the CDK-activating function of cyclin D1 is not necessary to induce either chromosomal instability or mammary tumorigenesis. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-07-06.

Cyclin D1 Mediates Resistance towards p53-Independent and -Dependent Apoptosis through Anti-Apoptotic Factors and Molecular Chaperones.

Knockdown of Cyclin D1 Inhibits Proliferation, Induces Apoptosis, and Attenuates the Invasive Capacity of Human Glioblastoma Cells

Cyclin D2 Is Essential For Bcr-Mediated Proliferation And Cd5 B Cell Development

Activation by CD40 Ligand Shifts Bcl-2 Family Protein Expression from Death-by-Default to Survival-by-Default.

Cyclin D1-Positive Expression Associated with Prognostic Significance and Clinicopathological Characteristics By Paving the Way for Proliferation in Diffuse Large B-Cell Lymphomas

Cytokine-Driven Cell Cycling is Mediated Through Cdc25a

Roles of Phosphorylated P210bcr/abl and Hsp90 Protein in Apoptosis Induced by Berbamine in K562 Cells.

Novel Function of the Cyclin A Binding Site of E2F in Regulating P53-Induced Apoptosis in Response to DNA Damage

Cyclin D3 Compensates for Loss of Cyclin D2 in Mouse B-lymphocytes Activated Via the Antigen Receptor and CD40*

Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair

BCR targets cyclin D2 via Btk and the p85|[alpha]| subunit of PI3-K to induce cell cycle progression in primary mouse B cells

BCR-ABL and Interleukin 3 Promote Haematopoietic Cell Proliferation and Survival Through Modulation of Cyclin D2 and P27kip1 Expression

The Apoptosis-Associated Gamma-Ray Response Of Bcl-X(L) Depends On Normal P53 Function

BCR targets cyclin D2 via Btk and the p85 α subunit of PI3-K to induce cell cycle progression in primary mouse B cells

Abstract P5-06-09: Cyclin d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.

Atox1-Cyclin D1 Loop Activity is Critical for Survival of Tumor Cells with Inactivated

Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses

A Proteomic Analysis of Bcl-2 Regulation of Cell Cycle Arrest: Insight into the Mechanisms

Inhibitory Effect of Bcl-2 on P53-Mediated Transactivation Following Genotoxic Stress

Abstract P5-07-06: Kinase-independent Role of Cyclin D1 in Chromosomal Instability and Mammary Tumorigenesis